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 Abstract  
The calcium-sensing receptor (CaSR) is a homodimeric G-protein coupled receptor that signals via 
intracellular calcium (Ca2+i) mobilisation and phosphorylation of extracellular signal-regulated kinase 
(ERK) to regulate extracellular calcium (Ca2+e) homeostasis. The central importance of the CaSR in 
Ca2+e homeostasis has been demonstrated by the identification of loss- or gain-of-function CaSR 
mutations that lead to familial hypocalciuric hypercalcaemia (FHH) or autosomal dominant 
hypocalcaemia (ADH), respectively. However, the mechanisms determining whether the CaSR 
signals via Ca2+i or ERK have not been established, and we hypothesised that some CaSR residues, 
which are the site of both loss- and gain-of-function mutations, may act as molecular switches to 
direct signalling through these pathways. An analysis of CaSR mutations identified in >300 
hypercalcaemic and hypocalcaemic probands identified five “disease switch” residues (Gln27, 
Asn178, Ser657, Ser820 and Thr828) that are affected by FHH and ADH mutations. Functional 
expression studies involving HEK293 cells showed disease switch residue mutations to commonly 
display signalling bias., For example, two FHH-associated mutations (p.Asn178Asp and p.Ser820Ala) 
impaired Ca2+i signalling without altering ERK phosphorylation. In contrast, an ADH-associated 
p.Ser657Cys mutation uncoupled signalling by leading to increased Ca2+i mobilisation whilst 
decreasing ERK phosphorylation. Structural analysis of these five CaSR disease switch residues 
together with four reported disease switch residues revealed these residues to be located at 
conformationally active regions of the CaSR such as the extracellular dimer interface and 
transmembrane domain. Thus, our findings indicate that disease switch residues are located at sites 
critical for CaSR activation and play a role in mediating signalling bias. 
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 Introduction  
The calcium (Ca2+)-sensing receptor (CaSR), a member of class C G-protein coupled receptors 
(GPCRs), is highly expressed in the parathyroid glands and kidneys, and plays an essential role in 
extracellular Ca2+ (Ca2+e) homeostasis by regulating parathyroid hormone (PTH) release and urinary 
Ca2+ excretion (1). The CaSR is functionally active as a constitutive homodimer (2) with each 
monomer of the CaSR consisting of: a large extracellular domain (ECD) that has been recently 
crystallised and shown to comprise a ligand-binding bilobed venus fly-trap domain (VFTD) linked to 
a cysteine-rich domain (3, 4); and also a seven transmembrane domain (TMD) and intracellular 
domain (ICD), which are involved in activating downstream signalling proteins (5, 6) (Fig. 1A-B). 
The CaSR couples to two major signal transduction cascades that comprise: the Gq/11-phospholipase C 
(PLC)-mediated generation of inositol 1,4,5-trisphosphate (IP3), which induces a rapid rise in 
intracellular calcium (Ca2+i) concentrations (7); and the mitogen-activated protein kinase (MAPK) 
cascade, such as the extracellular signal-regulated kinase 1/2 (ERK) pathway (8). CaSR-mediated 
activation of MAPK signalling can occur by coupling to either the Gq/11 or Gi/o pathways (9), and also 
by a G-protein-independent mechanism involving β-arrestin proteins (10).  
The importance of the CaSR for the regulation of Ca2+e has been highlighted by the 
identification of >230 different germline loss- and gain-of-function CaSR mutations that give rise to 
disorders of Ca2+e homeostasis known as familial hypocalciuric hypercalcaemia type 1 (FHH1) and 
autosomal dominant hypocalcaemia type 1 (ADH1), respectively (11). Structural analysis has shown 
that FHH1- and ADH1-causing mutations usually affect different CaSR residues with FHH1-causing 
mutations being scattered throughout the VFTD and TMD regions (11), whilst ADH1-causing 
mutations cluster within the second extracellular loop of the VFTD (residues 116-136) (12), and also 
within transmembrane (TM) helices 6 and 7 and the intervening third extracellular loop (ECL) of the 
TMD (residues 819-837) (13). However, four CaSR residues have been shown to be the location of 
both germline loss- and gain-of-function mutations that cause FHH1 and ADH1, respectively, and are 
termed “switch” or “toggle” residues (4, 14). Three disease switch residues (Leu173, Pro221 and 
Glu297) are located within highly conserved regions of the VFTD that are involved in ligand binding 
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 (14, 15), and one disease switch residue (Asn802) is located in the third intracellular loop (ICL) of the 
TMD (16). The precise role of these disease switch residues in CaSR function remains to be 
elucidated, and one possibility is that these residues act as molecular switches, which influence the 
transitioning of the CaSR between active and inactive conformations and direct CaSR signalling via 
the Ca2+i or MAPK pathways. To gain further insights into the role of CaSR disease switch residues, 
we sought for additional residues affected by loss- and gain-of-function mutations, by analysis of 
familial hypocalciruic hypercalcaemia and autosomal dominant hypocalcaemia patients who had been 
referred to our centre for diagnostic genetic testing of the CASR gene. Furthermore, we determined the 
effect of disease switch residue mutations on CaSR-mediated Ca2+i and ERK signalling, and analysed 
the structural consequences of these mutations, using the recently determined crystal structures of the 
CaSR ECD (3, 4). 
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 Results 
Identification of five CaSR disease switch residues  
An analysis of CaSR mutations and variants identified in >300 index cases of FHH1 or ADH1 that 
had been referred to our centre in Oxford (UK) since 2005 together with a review of previously 
reported CaSR mutations (17) identified five disease switch residues, which are the location of both 
FHH1- and ADH1-associated mutations. Two of these disease switch residues (Gln27 and Asn178) 
are located in the CaSR ECD. The Gln27 residue is affected by a novel FHH1-associated p.Gln27Pro 
variant and a reported FHH1-associated p.Gln27Arg mutation (18), and also a novel ADH1-
associated p.Gln27Glu variant (Table 1, Fig. 1 and Fig. S1); whereas the Asn178 residue is affected 
by a reported FHH1-associated p.Asn178Asp mutation (19), and also by a novel ADH1-associated 
p.Asn178Tyr variant. Two disease switch residues (Ser657 and Ser820) are located in the CaSR 
TMD. The Ser657 residue in TM3 is affected by a reported FHH1-associated p.Ser657Tyr mutation 
(20) and by a novel ADH1-associated p.Ser657Cys variant; whereas the Ser820 residue in TM6 is 
affected by a novel FHH1-associated p.Ser820Ala variant and a reported ADH1-associated 
p.Ser820Phe mutation (21). One disease switch residue (Thr828) was shown to be located in ECL3, 
which links TM6 and TM7 of the CaSR, and this residue is affected by a novel FHH1-associated 
p.Thr828Ile variant and a novel ADH1-associated p.Thr828Asn variant (Table 1 and Fig. 1). The 
novel DNA sequence abnormalities identified in this study were absent in >60,700 exomes from the 
Exome Aggregation Consortium (ExAC) cohort (22), and also affected evolutionary conserved CaSR 
residues (Fig. 1D-G). Moreover, bioinformatics analyses predicted that these novel variants likely 
represent pathogenic mutations (Polyphen-2 score >0.90, MutationTasting score >0.99) (Table S1). 
Thus, this analysis has identified five residues that are sites of both FHH1- and ADH1-associated 
mutations or variants, and these residues may potentially represent molecular disease switches 
involved in CaSR activation.    
 
Signalling responses of CaSR disease switch residue mutations 
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 To evaluate the effect of the five FHH1- and ADH1-associated ECD and TMD disease switch residue 
mutations and variants on CaSR-mediated signalling, HEK293 cells were transiently transfected with 
pEGFP-N1-CaSR constructs expressing WT or mutant CaSR (Fig. S2), and Ca2+i mobilisation and 
MAPK signalling was assessed following stimulation with Ca2+e, as reported (10).  
ECD disease switch residues: An assessment of Ca2+i mobilisation mediated by Gln27 disease switch 
residue mutations showed the novel FHH1-associated Pro27 variant protein to cause a rightward shift 
of the concentration-response curve and led to a significantly increased EC50 value compared to WT 
expressing cells (Fig. 2A-B), consistent with the p.Gln27Pro variant representing a pathogenic loss-
of-function CaSR mutation. However, the reported FHH1-associated Arg27 mutant CaSR (18) did not 
alter the EC50 value (Fig. 2B and Table S2), although it did lead to significantly reduced 
Ca2+i responses following stimulation with 5-7.5 mM Ca2+e (Fig. 2A). Conversely, cells expressing the 
novel ADH1-associated Glu27 variant had significantly elevated maximal responses, although EC50 
values were similar when compared with WT-expressing cells (Fig. 2A-B and Table S2). To further 
characterise the effects of the Gln27 residue mutations and variants on Ca2+i responses, a luciferase 
reporter containing a response element for nuclear factor of activated T-cells (NFAT), which is 
commonly used as a downstream mediator of Ca2+i signalling (23-25) was utilised. HEK293 cells 
expressing the FHH1-associated Pro27 and Arg27 CaSR proteins had significantly reduced NFAT 
fold-change responses compared to WT cells, consistent with a loss-of-function; whilst the ADH1-
associated Glu27 CaSR variant was associated with an elevated NFAT response, consistent with a 
gain-of-function (Fig. 2C). The effects of the Gln27 residue mutations on MAPK signalling were 
assessed by measuring fold-change ERK phosphorylation (pERK) responses following exposure to 
increasing Ca2+e concentrations ([Ca2+]e). Stimulation with Ca2+e induced a concentration-dependent 
increase in pERK responses in WT, Arg27 and Glu27 CaSR-expressing cells (Fig. 2D). These 
responses were significantly reduced at 5-7.5mM Ca2+e for the FHH1-associated Arg27 mutant 
compared to WT, whereas cells expressing the FHH1-associated Pro27 mutant had absent pERK 
responses (Fig. 2D). The ADH1-associated Glu27 mutant had significantly elevated pERK responses 
at 1-10mM Ca2+e, consistent with a gain-of-function in MAPK signalling (Fig. 2D and Table S2). The 
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 effects of the Gln27 mutants on MAPK signalling were also assessed by measuring gene transcription 
induced by a serum-response element (SRE)-containing luciferase reporter construct, which is a 
downstream mediator of ERK signalling (26, 27). These SRE responses were consistent with the 
pERK responses and indicate that the FHH1-associated Pro27 mutant abolished MAPK signalling 
(Fig. 2E), and thus exhibits an extreme bias towards Ca2+i signalling (Fig. 2F and Table S2); whereas 
the ADH1-associated Glu27 mutant had significantly elevated SRE responses and showed bias 
towards the MAPK pathway when compared to WT (Fig. 2F and Table S2).   
Functional assessment of mutations affecting the Asn178 disease switch residue showed the 
reported FHH1-associated Asp178 mutant (19) to cause a rightward shift of the Ca2+i concentration-
response curve and lead to significantly increased EC50 and maximal Ca2+i responses (Fig. 3A-B and 
Table S2). In contrast, cells expressing the novel ADH1-associated Tyr178 variant showed a leftward 
shift of the concentration-response curve and significantly reduced EC50 compared to WT cells (Fig. 
3A-B), consistent with the p.Asn178Tyr variant representing a pathogenic gain-of-function CaSR 
mutation. In keeping with these findings, NFAT reporter responses were also significantly reduced for 
the FHH1-associated Asp178 mutant and significantly increased for the ADH1-associated Tyr178 
mutant (Fig. 3C), thereby indicating that these mutations cause a loss- and gain of Ca2+i mobilisation, 
respectively. Evaluation of MAPK signalling showed the ADH1-associated Tyr178 mutant to cause a 
small but significant increase in pERK responses, whereas the FHH1-associated Asn178 mutant did 
not impair pERK or SRE reporter responses (Fig. 3D-E). Thus, the loss-of-function Asp178 mutant 
displayed a bias towards activation of pERK signalling when compared to Ca2+i mobilisation, whilst 
the gain-of-function Tyr178 mutant favoured signalling by the Ca2+i mobilisation pathway, similarly 
to WT CaSR (Fig. 3F and Table S2). 
TMD disease switch residues: An assessment of Ca2+i mobilisation mediated by Ser657 disease switch 
residue mutations showed the reported FHH1-associated Tyr657 mutant (20) to cause significantly 
decreased Ca2+e-mediated Ca2+i maximal responses, and a significantly elevated Ca2+i EC50 value 
compared to WT (Fig. 4A-B and Table S2). The novel ADH1-associated Cys657 variant led to 
significantly increased maximal Ca2+i responses, although the Ca2+i EC50 response of the Cys657 
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 protein was not significantly altered compared to WT (Fig. 4A-B and Table S2). To further 
characterise the functional consequences of the Ser657 residue mutations and variants, Ca2+i responses 
were determined using the NFAT reporter assay. This showed the FHH1-associated Tyr657 mutant to 
have abolished NFAT reporter responses, whereas the novel ADH1-associated Cys657 variant 
displayed significantly increased NFAT reporter activity (Fig. 4C), consistent with this representing a 
pathogenic gain-of-function CaSR mutation. An assessment of MAPK signalling showed the FHH1-
associated Tyr657 mutant to have significantly reduced pERK and SRE reporter responses (Fig. 4D-
E) consistent with this mutation leading to CaSR inactivation. In contrast, the ADH1-associated 
Cys657 mutant did not alter pERK or SRE reporter responses unless stimulated with 
supraphysiological (≥7.5mM) [Ca2+e], which caused this mutant to have significantly impaired MAPK 
signalling (Fig. 4D-E). Thus, the FHH1-associated Tyr657 and ADH1-associated Cys657 mutant 
CaSR proteins result in biased signalling towards the Ca2+i pathway (Fig. 4F and Table S2).   
Functional assessment of mutations affecting the Ser820 disease switch residue showed the 
novel FHH1-associated Ala820 variant to cause a rightward shift of the concentration-response curve 
and significantly increased EC50 value (Fig. 5A-B), which indicated that this represents a pathogenic 
loss-of-function CaSR mutation. Whereas, the reported ADH1-associated Phe820 mutant (21) showed 
a significantly reduced EC50 value (Fig. 5A-B), consistent with a gain of CaSR function. In keeping 
with these findings, the ADH1-associated Phe820 mutant showed significantly elevated NFAT 
reporter responses at 1-2.5mM [Ca2+]e, whilst the FHH1-associated Ala820 mutant showed reduced 
NFAT reporter responses at 7.5 mM [Ca2+]e (Fig. 5C). Assessment of MAPK responses revealed that 
the FHH1-associated Ala820 mutant induced a modest reduction in pERK responses following 
stimulation with 7.5 mM [Ca2+]e, and had no effect on SRE reporter responses when compared to WT 
(Fig. 5D-E). The ADH1-associated Phe820 mutant showed a bimodal effect on MAPK signalling, 
with a significant increase in pERK and SRE responses at low [Ca2+]e (1-2.5mM), but reduced 
responses at high [Ca2+]e (5-10mM) compared to WT (Fig. 5D-E). Bias plots demonstrated that the 
FHH1-associated Ala820 mutant was biased towards MAPK signalling, whilst the Phe820 cells was 
biased towards Ca2+i signalling, similar to WT (Fig. 5F).    
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 ECL3 disease switch residue: Functional assessment of mutations affecting the Thr828 disease switch 
residue showed the novel FHH1-associated Ile828 variant to cause significantly decreased Ca2+e-
mediated Ca2+i maximal responses, whilst the novel ADH1-associated Asn828 variant led to 
significantly increased Ca2+i responses and reduced EC50 value compared to WT (Fig. 6A-B). To 
further characterise the functional consequences of the Thr828 residue variants, Ca2+i responses were 
determined using the NFAT reporter assay. This showed the FHH1-associated Ile828 variant to have 
significantly reduced NFAT responses, whereas the ADH1-associated Asn828 variant had 
significantly increased NFAT responses (Fig. 6C), consistent with these variants representing 
pathogenic loss- and gain-of-function CaSR mutations, respectively. In keeping with the findings of 
the Ca2+i signalling studies (Fig. 6A-C), an assessment of MAPK signalling showed the FHH1-
associated Ile828 mutation to have significantly reduced pERK and SRE responses, whereas the 
ADH1-associated Asn828 mutation had significantly increased MAPK responses (Fig. 6D-E). Bias 
plots showed that both FHH1 and ADH1 mutants at the 828 residue had similar bias towards the Ca2+i 
pathway to WT expressing cells (Fig. 6F).    
 
Cellular expression of CaSR disease switch residue mutations 
Western blot analysis of whole cell lysates and plasma membrane fractions of HEK293 cells 
transiently transfected with WT or mutant CaSR disease switch residue proteins was undertaken to 
determine whether alterations in cellular expression may have contributed to the loss- and gain-of-
function caused by these mutant proteins. Untransfected HEK293 cells were shown not to 
endogenously express CaSR protein (Fig. S3A), whereas transfected cells expressed the monomeric 
CaSR as two bands at 140 and 160kDa, and the dimeric CaSR at ~250kDa (Fig. S3A), consistent with 
previous reports (28). An assessment of the FHH1-associated and ADH1-associated ECD Gln27 and 
Asn178 disease switch residue mutations showed no alterations in the total cellular or cell-surface 
expression of the monomeric and dimeric forms of the CaSR compared to WT (Fig. S3B-C). In 
contrast, reduced total and cell surface expression was observed for the FHH1-associated TMD 
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 Tyr657 mutant protein (Fig. S3D), as reported (29). However, no alterations in expression were noted 
for mutations affecting the TMD Ser820 and Thr828 CaSR residues (Fig. S3E-F).  
 
Structural characterisation of the CaSR disease switch residues 
The reported crystal structures of the ligand- and non-ligand bound forms of the homodimeric form of 
the bi-lobed CaSR ECD (3, 4) were analysed to determine whether the ECD disease switch residues 
(Gln27 and Asn178) may act as molecular switches that could influence the adoption of the CaSR into 
an active or inactive conformation (Fig. 7A-E). Such crystal structures for the CaSR TMD are not 
established, and the structural properties of the TMD and ECL3 disease switch residues (Ser657, 
Ser820 and Thr828) were therefore characterised using a homology model of the CaSR TMD (Fig. 
7F-H), that is based on the crystal structure of human metabotropic glutamate receptor type 1 
(mGluR1) in the inactive state, as previously described (10, 30). The location of the four previously 
reported CaSR disease switch residues (Leu173, Pro221, Glu297 and Asn802) (14-16) were also 
mapped onto the ECD and TMD of the CaSR (Fig. 1A-B, Fig. 7F and Fig. S1). 
ECD disease switch residues: The Gln27 disease switch residue is located within lobe 1 of the VFTD, 
and forms hydrogen bonds with the adjacent His344 (Fig. 7A-C). The side chain of Gln27 adopts 
similar conformations in all crystal structures (Fig. 7B), and the FHH1-associated p.Gln27Pro (Fig. 
7B-C) mutation is predicted to abolish a hydrogen bond between an amino group of Gln27 and a 
carbonyl oxygen of His344 (Fig. 7B-C). A similar analysis of the FHH1-associated p.Gln27Arg and 
ADH1-associated p.Gln27Glu mutations did not reveal the occurrence of any structural alterations 
involving the VFTD, using the available crystal structures (3, 4). The Asn178 disease switch residue 
is located at the lobe 1-lobe 1 VFTD dimer interface (Fig. 1 and Fig. 7D-E), and in the inactive 
conformation (Fig. 7D), forms an intramolecular hydrogen bond with the neighbouring Asn176 
residue. However, in the active (ligand-bound) conformation (Fig. 7E), Asn178 could participate in 
hydrophilic interactions with the neighbouring Asn176 residue and form hydrogen bond interactions 
with Tyr246 from the opposing molecule in the CaSR dimer, thereby stabilising an active 
10 
 
 conformation of CaSR (3). The FHH1-associated p.Asn178Asp mutation is predicted to introduce a 
negative charge at the dimer interface, which could lead to repulsion between Asp178 and Asp48 
from the opposing molecule in the active conformation (Fig. 7E). Thus, the p.Asn178Asp mutation 
may impair dimerisation and destabilise the active CaSR conformation. In contrast, the ADH1-
associated Asn178Tyr mutation is predicted to introduce a bulky residue at the dimer interface, that 
may potentially form pi-pi interactions with Tyr246 from the opposing molecule and stabilise the 
CaSR dimer (Fig. 7E), thereby leading to CaSR activation. Structural analysis also showed that the 
reported Leu173 (lobe 1) and Pro221 (lobe 2) disease switch residues (14) are located at the hinge 
region of the VFTD dimer interface, whilst the reported Glu297 disease switch residue (15) is located 
within the VFTD cleft which is involved in ligand binding (Fig. 1A and Fig. S1) (3). 
TMD and ECL3 disease switch residues: The Ser657 disease switch residue is located in the middle 
of TM2 (Fig. 7F) and its side chain projects towards Cys691 of TM3 (Fig. 7G). The FHH1-associated 
p.Ser657Tyr mutation would introduce a bulky side-chain, which may disrupt the TM2-TM3 
interactions. In contrast, the ADH1-associated p.Ser657Cys mutation would place two Cys residues in 
close proximity, and this may lead to the formation of a disulphide bond between TM2 and TM3 (Fig. 
7G) that could potentially stabilise the CaSR in an active conformation. The Ser820 disease switch 
residue is located in the middle of TM6, whilst Thr828 is in ECL3, which connects TM6 with TM7 
(Fig. 7F and 7H). The reported Asn802 disease switch residue (16) is also located in the distal TMD, 
and is situated in ICL3, which connects TM5 with TM6 (Fig. 7F). Homology model analysis did not 
predict any interactions between these distal TMD disease switch residues and neighbouring amino 
acid residues. However, these residues (Ser657, Asn802, Ser820 and Thr828) are located within or 
adjacent to TM3 and TM6, which can undergo large conformational changes important for G-protein 
binding (31, 32), and thus these disease switch residues may potentially affect G-protein activation 
without influencing interactions with neighbouring residues.  
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 Discussion 
Our studies have identified five CaSR disease switch residues, and these findings together with the 
four previously reported disease switch residues (14-16), indicate that the CaSR has at least nine 
disease switch residues, which are the location of both germline loss- and gain-of-function mutations 
that lead to FHH1 and ADH1, respectively (Fig. 1). The finding that different mutations affecting the 
same residue may lead to distinct genetic disorders agrees with previous studies of the human 
vasopressin type 2 receptor (V2R), which is a class A GPCR involved in the regulation of renal water 
excretion (33, 34). Thus, a loss-of-function germline mutation affecting the highly conserved Arg137 
residue of the V2R, which is located in the TMD, has been shown to cause nephrogenic diabetes 
insipidus, which is characterised by excess renal water loss (33), whereas, gain-of-function mutations 
of the V2R Arg137 residue give rise to inappropriate renal water retention that causes the nephrogenic 
syndrome of inappropriate antidiuresis (NSIAD) (34). 
Structural analysis of the CaSR demonstrated that four extracellular disease switch residues 
are located in key sites within the VFTD (Fig. S1 and Fig. 7). Thus, the reported Glu297 disease 
switch residue (15) is located within the cleft formed by lobes 1 and 2 of the VFTD (Fig. 1) and has 
been shown to be involved in ligand binding which in turn leads to CaSR activation by mediating 
closure of the two lobes of the VFTD (3). Whereas, the Leu173, Asn178 and Pro221 disease switch 
residues are located in the proximity of the hinge region (Fig. 1A and Fig. S1) between lobes 1 and 2, 
and also at the extended dimer interface that is formed by the two protomers of the VFTD upon 
agonist-mediated CaSR activation (Fig. 1) (3). Moreover, three of the TMD disease switch residues 
clustered around TM6 (Fig. 1 and Fig. 7), which has been shown in structural studies of class A and B 
GPCRs to undergo a substantial outward movement in order to accommodate G-protein binding 
during receptor activation (35-37). Our finding that ECD and TMD CaSR disease switch residues are 
located within regions that undergo large conformational changes upon ligand binding is consistent 
with an analysis of molecular switch residues identified in class A GPCRs, which has shown these to 
be located between the GPCR ligand-binding pocket and the G-protein interaction site (38). In this 
region of the TMD, class A GPCR molecular switch residues were shown to particularly cluster 
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 around the kink region of TM6, which undergoes the greatest structural alteration during receptor 
activation (38). Moreover, large conformational changes upon ligand binding involving residues 
within TM3 and TM6 have also been shown to be important in class C GPCR activation and G-
protein coupling (39, 40).  
We used CaSR crystal structures (3, 4) to obtain detailed insights into how the two VFTD 
disease switch residues identified in this study may be influencing CaSR activation. Our analysis 
indicated that the Asn178 residue adopts distinct conformations and forms different interactions in the 
ligand-bound and unbound forms of the CaSR (Fig. 7D-E). In the inactive CaSR, Asn178 forms weak 
intramolecular hydrogen bonds with Asn176, whereas upon ligand binding Asn178 interacts with the 
opposing molecule and could facilitate agonist-induced dimerisation of the VFTD, which in turn 
triggers CaSR-mediated signal transduction (3). It is therefore possible that the Asn178 residue and its 
mutations may disease switch the CaSR between active and inactive conformations. This finding that 
residues affected by loss- and gain-of-function mutations can act as molecular switches is consistent 
with that previously reported for the Arg137 molecular switch residue of the human V2R, which 
participates in an ionic lock mechanism common to class A GPCRs, and determines whether these 
receptors adopt active or inactive conformations (33, 34). However, our analysis of the Gln27 residue 
within the context of the available crystal structures, revealed that this residue was unlikely to be 
acting as a molecular switch as its interactions with other residues did not change upon CaSR 
activation (Fig. 7B). Moreover, Gln27 is not located in a region directly involved in ligand-binding or 
in mediating large conformational changes. Instead, the finding that Gln27 mutations can lead to loss- 
or gain-of-function is most likely a consequence of the specific mutations affecting this residue rather 
than due to the properties of the WT residue. Detailed structural analysis of the TMD disease switch 
residues was not possible because the crystal structure of the CaSR TMD has not been established. 
However, homology modeling of the CaSR TMD based on the crystal structure of the related mGluR1 
(10) provided insights into the role of the Ser657 disease switch residue, which may mediate 
interactions between TM2 and TM3 (Fig. 7G). It should be noted that all of the TMD disease switch 
residues detected to-date (Ser657, Asn802, Ser820 and Thr828) have polar side-chains. Previous 
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 studies of class A GPCRs have shown that conserved TMD polar residues contribute to a water-
mediated hydrogen bonded network within the TMD that plays a key role in regulating receptor 
activity, and that engineered alanine substitutions of these residues can cause loss or gain of receptor 
function (41). Thus, the polar TMD disease switch residues may potentially play a complex role in 
mediating interactions between the different helices within the CaSR TMD. 
In vitro functional expression studies of mutations affecting the five disease switch residues 
identified in this study have provided insights into the role of these residues in mediating CaSR signal 
transduction. For example, most of the disease switch residue mutations showed similar levels of cell-
surface expression compared to WT CaSR (Fig. S3), and it is thus unlikely that the alterations in 
signalling caused by these mutants is a consequence of altered anterograde or retrograde receptor 
trafficking. Moreover, none of the disease switch residue mutations had significant effects on CaSR 
function in the absence of the agonist (Ca2+e), and therefore these disease switch residues are not 
involved in regulating the basal activity of the CaSR. However, mutations affecting the Gln27, Ser657 
and Thr828 disease switch residues altered the maximal responses of the CaSR without influencing 
EC50 values, which may indicate that these mutations altered the intrinsic signalling efficacy of the 
CaSR without affecting agonist affinity (42). Another possibility is that the alterations in maximal 
Ca2+i responses may be due to changes in cell-surface expression of the CaSR switch residue mutants. 
However, an alteration in cell-surface expression was only demonstrated for the Tyr657 disease 
switch residue mutant. Moreover, in contrast with other ADH1-associated disease switch residue 
mutants, which showed increased maximal Ca2+i responses, the gain-of-function Phe820 disease 
switch residue mutant showed reduced maximal Ca2+i responses compared to WT, which indicates 
that the CaSR activation caused by this mutant may have led to depletion of intracellular stores of 
Ca2+, as reported (29).  
As most of the nine CaSR disease switch residues are located in regions of the CaSR which 
are predicted to undergo conformational rearrangements upon ligand binding (Fig. 1 and Fig. 7) (3), 
mutations affecting these residues have the potential to stabilise the CaSR in conformations that 
selectively activate G-protein dependent or independent signalling pathways (43). In keeping with 
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 this, many of the CaSR disease switch residue mutations showed distinct patterns of signalling bias 
compared to the WT CaSR, which preferentially activates Ca2+i mobilisation (29). The disease switch 
residue mutations were commonly found to show signalling bias towards either Ca2+i (FHH1-
associated p.Gln27Pro or ADH1-associated p.Asn178Tyr and p.Ser657Cys) or MAPK pathway 
activation (FHH1-associated p.Asn178Asp and p.Ser820Ala, or ADH1-associated p.Gln27Glu). In 
particular, the FHH1-associated p.Asn178Asp and p.Ser820Ala mutations led to reductions in Ca2+i 
mobilisation without any significant impairment of pERK responses. Thus, these mutations may result 
in the CaSR adopting conformational states that favour signalling away from Gq/11-mediated PLC 
activation and towards Gi/o and/or β-arrestin-mediated MAPK signalling, as has been recently 
demonstrated for a CaSR mutation that disrupts a salt-bridge within the TMD (10). In contrast, the 
ADH1-associated p.Ser657Cys disease switch residue mutation showed signalling bias towards Ca2+i 
mobilisation, as this mutation significantly increased Ca2+i responses, yet led to a reduction in MAPK 
signalling as assessed by pERK and SRE reporter responses (Fig. 4). To our knowledge, this is the 
first disease-causing CaSR mutation reported to cause both loss- and gain-of-function, depending on 
which signalling pathway is evaluated, and highlights a potential uncoupling of Ca2+i and MAPK 
responses. This understanding of signalling bias caused by CaSR mutations may provide a precision 
medicine approach to the treatment of patients with symptomatic forms of FHH1 and ADH1. For 
example, FHH1 patients harbouring a CaSR mutation such as p.Ser820Ala, which shows a 
preferential impairment of Ca2+i responses may benefit from treatment with cinacalcet, as this CaSR 
positive allosteric modulator (PAM) is biased towards the Ca2+i mobilisation pathway (44), whereas 
FHH1-causing mutations such as p.Thr828Ile that cause a preferential reduction in MAPK signalling 
may benefit from treatment with the AC265347 compound, as this CaSR PAM causes biased 
activation of pERK (45). 
 In conclusion, our studies have demonstrated that CaSR residues affected by disease-causing 
loss- and-gain-of-function mutations are located within receptor domains that are pivotal for CaSR 
function and may undergo conformational rearrangements during GPCR activation. Moreover, these 
disease switch residues likely determine whether the CaSR signals via Ca2+i or MAPK pathways.    
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 Materials and Methods 
Bioinformatic analysis of DNA sequence variants  
Publicly accessible databases (dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/) (46) and the 
Exome Aggregation Consortium (ExAC) (exac.broadinstitute.org) which contains details from 
exomes of 60,706 unrelated individuals (22)), were examined for the presence of CASR sequence 
variants. 
 
Protein sequence alignment and structural analysis 
Protein sequences of CaSR orthologs were aligned using ClustalOmega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) (47). Crystal structures of CaSR ECDs in both active and 
inactive conformations were analysed (Protein Data Bank (PDB) accession codes 5FBK, 5FBH, 
5K5S, 5K5T) (3, 4). The HHpred homology detection server 
(https://toolkit.tuebingen.mpg.de/hhpred) was used to identify crystal structures with similar 
sequences to the CaSR TMD, and to perform amino acid sequence alignment (30, 48). The CaSR 
sequence was threaded onto the mGluR1 (PDB ID 4OR2) (30) template coordinates using Modeller 
(https://toolkit.tuebingen.mpg.de/modeller) to construct a homology model (49). Figures were 
prepared using the PyMOL Molecular Graphics System (Schrodinger, LLC). 
 
Cell culture and transfection 
Studies were performed in HEK293 cells maintained in DMEM-Glutamax media (ThermoFisher) 
with 10% fetal bovine serum (Gibco) at 37ºC, 5% CO2. Mutations were introduced into the reported 
WT pEGFP-N1-CaSR construct by site-directed mutagenesis using the Quikchange Lightning Kit 
(Agilent Technologies) and gene-specific primers (SigmaAldrich), as described. WT and mutant 
pEGFP-N1-CaSR constructs, and luciferase reporter constructs (pGL4.30-NFAT and pGL4.33-SRE, 
Promega) were transiently transfected into HEK293 cells using Lipofectamine 2000 
(LifeTechnologies) 48 hours before experiments, as described (50).  
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Western blot analyses 
Expression of WT and mutant proteins by the pEGFP-N1-CaSR constructs was confirmed by Western 
blot analysis, with the calnexin housekeeping protein being used as a loading control (50). For cell 
fractionation studies, cells were transfected with CaSR constructs and 48 hours later plasma 
membrane and cytoplasmic fractions were isolated using a plasma membrane extraction kit (Catalog 
No 65400, Abcam), as described (51). Plasma membrane calcium ATPase (PMCA1) protein was used 
as a loading control for plasma membrane fractions. The following primary antibodies were used for 
Western blot analysis: anti-CaSR (ADD, ab19347, Abcam), anti-calnexin (ab2301, Millipore), anti-
PMCA1 (ab190355, Abcam).  The Western blots were visualised using an Immuno-Star WesternC kit 
(BioRad) on a BioRad Chemidoc XRS+ system (50). 
 
Intracellular calcium measurements 
Ca2+e-induced Ca2+i responses were measured by Fluo-4 calcium assays as previously described (52). 
HEK293 cells were plated in 96-well plates (Corning), and transiently transfected with 1000ng/mL 
WT or mutant pEGFP-N1-CaSR constructs. Ten wells were transfected with each construct. Cells 
were loaded with Fluo-4 dye, prepared according to manufacturer’s instructions (Invitrogen), for 30-
60 minutes at 37°C. Baseline measurements were made for each well and increasing doses of CaCl2 
injected automatically into each well. One well was used for each [Ca2+]e. Changes in Ca2+i were 
recorded on a PHERAstar instrument (BMG Labtech) at 37°C with an excitation filter of 485nm and 
an emission filter of 520nm. The peak mean fluorescence ratio of the transient response following 
each individual stimulus was measured using MARS data analysis software (BMG Labtech). 
Responses were normalised to the maximal response of WT expressing cells and plotted using 
GraphPad Prism (29). Assays were performed in 4-12 biological replicates (independently transfected 
wells on separate plates, performed on at least 4 different days) for each of the expression constructs. 
Statistical analysis was performed using two-way ANOVA and the F-test for EC50 values (50, 52). 
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Functional assays 
AlphaScreen assays were undertaken to measure pERK using cells transiently transfected with 100ng 
of WT or mutant pEGFP-N1-CaSR constructs. Cells were treated with 0.1-10mM CaCl2 for 5 minutes 
then lysed in Surefire lysis buffer and pERK and total ERK assays performed, as previously described 
(10, 52) . The fluorescence signal in AlphaScreen assays was measured using the PHERAstar FS 
microplate reader (BMG Labtech) (10, 52) . Assays were performed in 6-12 biological replicates 
(independently transfected wells, performed on at least 3 different days) for each of the expression 
constructs.  Luciferase reporter assays were undertaken to measure SRE and NFAT responses, as 
previously described (50, 52). Cells were transiently transfected with 100ng/ml of the WT or mutant 
pEGFP-N1-CaSR constructs, 100ng/ml luciferase construct (either pGL4-NFAT or pGL4-SRE) and 
10ng/ml pRL. At 48 hours post-transfection, cells were then treated with 0-10mM CaCl2 and 
incubated for 4 hours prior to lysis and measurement of luciferase activity using Dual-Glo Luciferase 
(Promega) on a Veritas Luminometer (Promega), as previously described (50). Luciferase:renilla 
ratios were expressed as fold-changes relative to responses at basal CaCl2 concentrations (0.1mM). 
Assays were performed in 8-12 biological replicates (independently transfected wells, performed on at 
least 4 different days) for each of the expression constructs. Statistical analysis was performed using 
two-way ANOVA. To construct the bias plots the responses at each [Ca2+]e in Ca2+i (x-axis) and 
pERK (y-axis) assays, were plotted against each other, as previously described (29). Data was 
normalised to WT levels, expressed between 0 and 100%. If the agonist showed no preference for one 
pathway over another the concentration-response curves would be coincident, and the bias plot would 
overlay the line of identity (dotted line in figures) (29). If the WT or mutant CaSR couples more 
favourably to one pathway over another, the bias plot line will fall on either side of the line towards 
the preferred pathway.    
 
Bias Factor Calculation 
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 Bias factor calculations were based on previous studies (53, 54). To normalise data, responses of each 
mutant CaSR construct was expressed relative to WT as a percentage. Nonlinear regression of 
concentration-response curves was performed with GraphPad Prism (GraphPad) and the EC50 and 
Emax calculated. The intrinsic relative activity (RAi) value was calculated using the following equation 
for each mutant and WT CaSR:  
 
where ‘.1’ denotes response 1 (Ca2+i) and ‘.2’ denotes response 2. The bias factor was calculated 
relative to WT as follows: 
 
 
Statistical analysis 
A minimum of four independent biological replicates (independently transfected wells, performed on 
at least 3 different days) were used for all statistical comparisons. All data was analysed by 2-way 
ANOVA with Tukey’s multiple-comparisons test. Statistical analyses were undertaken using 
GraphPad Prism (GraphPad), and a value of p<0.05 was considered significant for all analyses. 
Comparison of EC50 values was performed using the F-test (50, 52). 
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 Legends to Figures 
Figure 1. Location and evolutionary conservation of five CaSR disease switch residues  
 (A) The crystal structure of the homodimeric human CaSR extracellular domain (ECD) (PDB ID 
5K5S) (3). Each CaSR ECD monomer is comprised of: a venus fly-trap domain (VFTD) consisting of 
two lobes (lobe 1 (red) and lobe 2 (blue)) joined by a hinge region, and a cysteine-rich domain 
(orange). Side chains of disease switch residues Gln27 and Asn178, and previously reported disease 
switch residues Leu173, Pro221 and Glu297 are shown as yellow spheres. Leu173 and Pro221 are 
located within the hinge region (Fig. S1). The calcium ions are shown as green spheres. (B) Schematic 
diagram of a CaSR monomer showing: the extracellular bi-lobed VFTD; seven transmembrane 
domain (TMD) helices (1-7) with extracellular loops (ECL1-3) and intracellular loops (ICL1-3); and 
the intracellular domain (ICD). Lobe 1 of the ECD is shown in red and lobe 2 in purple. The locations 
of the five disease switch residues (Gln27, Asn178, Ser657, Ser820 and Thr828) are indicated in 
orange, and reported disease switch residues are indicated in brown. (C) Schematic representation of 
the genomic organisation of the human CASR gene showing locations of the FHH1- and ADH1-
associated disease switch residue mutations identified in this study. The CASR gene consists of 7 
exons. Coding regions are shaded gray and untranslated regions are represented by open boxes. The 
ECD is encoded by exons 1-6 and the 5’ portion of exon 7, and the TMD and ICD by exon 7. The 
FHH1-associated (blue) and ADH1-associated (red) disease switch residue mutations are shown 
above and below the exons, respectively. (D-F) Multiple protein sequence alignment of (D) residues 
17-37 of the ECD β1-strand and β2-strand surrounding Gln27 (Q27); (E) residues 168-188 of the 
ECD α4-helix and β5-strand, surrounding Asn178 (N178) (3, 4); (F) residues 647-667 of 
transmembrane (TM) helix 2 surrounding Ser657 (S657); and (G) residues 815-836 of TM6 and 
ECL3 surrounding Ser820 (S820) and Thr828 (T828). 
 
Figure 2  Effect of the ECD Gln27 disease switch residue mutations on Ca2+i and pERK 
signalling 
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  (A) Concentration-response curves showing Ca2+i responses following stimulation with extracellular 
calcium in HEK293 cells expressing WT (Gln27, black), or FHH1-associated (Pro27 and Arg27, 
blue) or ADH1-associated (Glu27, red) mutant (m) CaSR proteins. Responses are expressed relative 
to the WT maximal responses with mean±SEM of 4-10 biological replicates. (B) EC50 values obtained 
from the Ca2+i concentration-response curves shown in panel A. (C-E) Concentration-response curves 
of extracellular calcium-induced: (C) NFAT luciferase reporter responses; (D) phosphorylated ERK 
(pERK) responses expressed as the ratio of pERK to total ERK concentrations; and (E) SRE reporter 
responses of HEK293 cells expressing WT (Gln27), or FHH1-associated (Pro27 and Arg27) or 
ADH1-associated (Glu27) mutant CaSR proteins. Responses at each extracellular calcium 
concentration ([Ca2+]e) are expressed as a fold-change of basal [Ca2+]e responses, and shown as 
mean±SEM of 6-12 biological replicates. (F) Bias plots for Ca2+i and pERK signalling responses of 
mutations affecting the Gln27 CaSR disease switch residue. Curves located above gray dotted line 
indicate signalling biased towards Ca2+i, whilst curves below gray dotted line indicate signalling 
biased towards pERK. Statistical analyses comparing WT vs. Pro27 (blue dollar) or Arg27 (blue 
asterisk), and WT vs. Glu27 (red asterisk) **** or $$$$p<0.0001, ***p<0.001, ** or $$p<0.01, * or 
$p<0.05 compared to WT, by a 2-way ANOVA with Tukey's multiple-comparisons test.  
 
Figure 3 Effect of the ECD Asn178 disease switch residue mutations on Ca2+i and pERK 
signalling 
 (A) Concentration-response curves showing Ca2+i responses following stimulation with extracellular 
calcium in HEK293 cells expressing WT (Asn178, black), or FHH1-associated (Asp178, blue) or 
ADH1-associated (Tyr178, red) mutant (m) CaSR proteins. Responses are expressed relative to the 
WT maximal responses with mean±SEM of 4-10 biological replicates. (B) EC50 values obtained from 
the Ca2+i concentration-response curves shown in panel A. (C-E) Concentration-response curves of 
extracellular calcium-induced: (C) NFAT luciferase reporter responses; (D) pERK responses 
expressed as the ratio of pERK to total ERK concentrations; and (E) SRE reporter responses of 
HEK293 cells expressing WT (Asn178), or FHH1-associated (Asp178) or ADH1-associated (Tyr178) 
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 mutant CaSR proteins. Responses at each [Ca2+]e are expressed as a fold-change of basal 
[Ca2+]e responses and shown as mean±SEM of 6-12 biological replicates. (F) Bias plots for Ca2+i and 
pERK signalling responses of mutations affecting the Asn178 CaSR disease switch residue. Curves 
located above gray dotted line indicate signalling biased towards Ca2+I, whilst curves below gray 
dotted line indicate signalling biased towards pERK. Statistical analyses comparing WT vs. Asp178 
(blue asterisk), and WT vs. Tyr178 (red asterisk) ****p<0.0001, **p<0.01, *p<0.05 compared to WT, 
by a 2-way ANOVA with Tukey's multiple-comparisons test. 
 
Figure 4  Effect of the TMD Ser657 disease switch residue mutations on Ca2+i and pERK 
signalling 
 (A) Concentration-response curves showing Ca2+i responses following stimulation with extracellular 
calcium in HEK293 cells expressing WT (Ser657, black), or FHH1-associated (Tyr657, blue) or 
ADH1-associated (Cys657, red) mutant (m) CaSR proteins. Responses are expressed relative to the 
WT maximal responses with mean±SEM of 4-10 biological replicates. (B) EC50 values obtained from 
the Ca2+i concentration-response curves shown in panel A. (C-E) Concentration-response curves of 
extracellular calcium-induced: (C) NFAT luciferase reporter responses; (D) pERK responses 
expressed as the ratio of pERK to total ERK concentrations; and (E) SRE reporter responses of 
HEK293 cells expressing WT (Ser657), or FHH1-associated (Tyr657) or ADH1-associated (Cys657) 
mutant CaSR proteins. Responses at each [Ca2+]e are expressed as a fold-change of basal 
[Ca2+]e responses and shown as mean±SEM of 6-12 biological replicates. (F) Bias plots for Ca2+i and 
pERK signalling responses of mutations affecting the Ser657 CaSR disease switch residue. Curves 
located above gray dotted line indicate signalling biased towards Ca2+I, whilst curves below gray 
dotted line indicate signalling biased towards pERK. Statistical analyses comparing WT vs. Tyr657 
(blue asterisk), and WT vs. Cys657 (red asterisk) ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05 
compared to WT, by a 2-way ANOVA with Tukey's multiple-comparisons test. 
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 Figure 5 Effect of the TMD Ser820 disease switch residue mutations on Ca2+i and pERK 
signalling 
Concentration-response curves showing Ca2+i responses following stimulation with extracellular 
calcium in HEK293 cells expressing WT (Ser820, black), or FHH1-associated (Ala820, blue) or 
ADH1-associated (Phe820, red) mutant (m) CaSR proteins. Responses are expressed relative to the 
WT maximal responses with mean±SEM of 4-10 biological replicates. (B) EC50 values obtained from 
the Ca2+i concentration-response curves shown in panel A. (C-E) Concentration-response curves of 
extracellular calcium-induced: (C) NFAT luciferase reporter responses; (D) pERK responses 
expressed as the ratio of pERK to total ERK concentrations; and (E) SRE reporter responses of 
HEK293 cells expressing WT (Ser820), or FHH1-associated (Ala820) or ADH1-associated (Phe820) 
mutant CaSR proteins. Responses at each [Ca2+]e are expressed as a fold-change of basal 
[Ca2+]e responses and shown as mean±SEM of 6-12 biological replicates. (F) Bias plots for Ca2+i and 
pERK signalling responses of mutations affecting the Ser820 CaSR disease switch residue. Curves 
located above gray dotted line indicate signalling biased towards Ca2+i, whilst curves below gray 
dotted line indicate signalling biased towards pERK. Statistical analyses comparing WT vs. Ala820 
(blue asterisk), and WT vs. Phe820 (red asterisk) ****p<0.0001, **p<0.01, *p<0.05 compared to 
WT, by a 2-way ANOVA with Tukey's multiple-comparisons test. 
 
Figure 6 Effect of the TMD Thr828 disease switch residue mutations on Ca2+i and pERK 
signalling 
Concentration-response curves showing Ca2+i responses following stimulation with extracellular 
calcium in HEK293 cells expressing WT (Thr828, black), or FHH1-associated (Ile828, blue) or 
ADH1-associated (Asn828, red) mutant (m) CaSR proteins. Responses are expressed relative to the 
WT maximal responses with mean±SEM of 4-10 biological replicates. (B) EC50 values obtained from 
the Ca2+i concentration-response curves shown in panel A. (C-E) Concentration-response curves of 
extracellular calcium-induced: (C) NFAT luciferase reporter responses; (D) pERK responses 
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 expressed as the ratio of pERK to total ERK concentrations; and (E) SRE reporter responses of 
HEK293 cells expressing WT (Thr828), or FHH1-associated (Ile828) or ADH1-associated (Asn828) 
mutant CaSR proteins. Responses at each [Ca2+]e are expressed as a fold-change of basal 
[Ca2+]e responses and shown as mean±SEM of 6-12 biological replicates. (F) Bias plots for Ca2+i and 
pERK signalling responses of mutations affecting the Thr828 CaSR disease switch residue. Curves 
located above gray dotted line indicate signalling biased towards Ca2+I, whilst curves below gray 
dotted line indicate signalling biased towards pERK. Statistical analyses comparing WT vs. Ile828 
(blue asterisk), and WT vs. Asn828 (red asterisk) ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05 
compared to WT, by a 2-way ANOVA with Tukey's multiple-comparisons test. 
 
Figure 7 Structural analysis of CaSR disease switch residues 
(A) The Gln27 residue is located in the β1-strand of lobe 1 of the CaSR ECD, shown in the active 
conformation (PDB: 5K5S) (3) (Fig. 1 and Fig. S1). The peptide backbone amino group hydrogen on 
nitrogen (blue) of Gln27 forms a hydrogen bond (H-bond) with the peptide carbonyl group of His344 
located in the α10-α11 loop. (B) Superposition of all known crystal structures of CaSR: active 
conformation (carbons are in dark red as in panels A and C; PDB: 5K5S (3)), inactive conformation 
(cyan, PDB: 5K5T (3)), cyclomethyltryptophan/magnesium-bound form (green, PDB: 5FBK (4)), 
cyclomethyltryptophan/magnesium/gadolinium-bound form (blue, PDB: 5FBH, (4)). The Gln27-
His344 interaction is not altered in the active and inactive conformations of the CaSR. (C) The FHH1-
associated p.Gln27Pro mutation abolishes the Gln27-His344 hydrogen bond (circled).  (D) The 
Asn178 is located at the lobe 1-lobe 1 dimer interface (Fig. 1 and Fig. S1). The side chain of Asn178 
is exposed to solvent in the inactive conformation (cyan, PDB: 5K5T (3)), and is positioned at ≥7.0Å 
from neighbouring residues (Asp48, Tyr246) on the opposing CaSR molecule. (E) The side chain of 
Asn178 is located within a tightly packed environment between two CaSR ECD protomers in the 
active conformation (PDB: 5K5S). Mutation to Asp178 or Tyr178 could alter the relative orientation 
between the two protomers. (F) Homology model of the CaSR transmembrane domain (TMD), 
viewed parallel to the cell membrane, and based on the structure of mGluR1 (PDB: 4OR2) (30). Side 
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 chains of Ser657, Asn802, Ser820, and Thr828 are shown as spheres (dashed circles). Seven TM 
helices are numbered. (G) The Ser657 residue is located within TM2 and its side chain projects 
towards Cys691 located on TM3. (H) The Ser820 residue is located within TM6 and its side chain 
points towards the transmembrane bilayer. The Thr828 residue is located within ECL3, which 
connects TM6 and TM7. 
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Table 1 FHH1- and ADH1-associated mutations affecting five CaSR disease switch 
residues  
 
aCodon number according to full-length 1078 amino acid CaSR protein. All variants were observed in 
the heterozygous state. 
 
Wild-type  FHH1 mutation  ADH1 mutation 
Codona  Nucleotide  Amino acid   Reference  Nucleotide  Amino acid   Reference 
Gln27 
 c.80A>C  Pro  This study  c.79C>G  Glu  This study 
 c.80A>G  Arg  (18)       
Asn178  c.562A>T  Asp  (19)  c.562A>T  Tyr  This study 
Ser657  c.1970C>A  Tyr  (20)  c.1970C>G  Cys  This study 
Ser820  c.2458T>G  Ala  This study  c.2459C>T  Phe  (21) 
Thr828  c.2483C>T  Ile  This study  c.2483C>A  Asn  This study 
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ABBREVIATIONS 
ADH1, autosomal dominant hypocalcaemia type 1; Ca2+e, extracellular calcium; Ca2+i, intracellular 
calcium; CaSR, calcium-sensing receptor; ECD, extracellular domain; ECL, extracellular loop; ERK, 
extracellular signal-regulated kinase 1/2; ExAc, exome aggregation consortium; FHH1, familial 
hypocalciuric hypercalcaemia type 1; GPCR, G-protein coupled receptor; ICD, intracellular domain; 
ICL, intracellular loop; IP3, inositol 1,4,5-trisphosphate; MAPK, mitogen-activated protein kinase; 
mGluR1, metabotropic glutamate receptor type 1; NFAT, nuclear factor of activated T-cells; NSIAD, 
nephrogenic syndrome of inappropriate antidiuresis; PDB, protein data bank; PLC, phospholipase C; 
pERK, phosphorylated ERK; PMCA1, plasma membrane calcium ATPase; PTH, parathyroid 
hormone; SRE, serum-response element; TM, transmembrane; TMD, TM domain; V2R, vasopressin 
type 2 receptor; VFTD, venus fly-trap domain 
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